🔎 Trials Near Me

Gara Jalqabaatti › Leukemia Myeloidii Hamaa › Vermont

Qorannoo klinikaalii Leukemia Myeloidii Hamaa Vermont keessatti

Qorannoo 7 Leukemia Myeloidii Hamaa f Vermont keessatti hirmaatuu jiru.

Magaalota Vermont keessatti

Takkalaa qorannoo (Ingiliffa)

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

  • University of Vermont Medical Center, Burlington
  • University of Vermont and State Agricultural College, Burlington
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 hanga 59 · Saalaa hunda · Haaromfame 28-Ful-2026 · NCT05554393

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

  • University of Vermont Medical Center, Burlington
  • University of Vermont and State Agricultural College, Burlington
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 25-Ful-2026 · NCT05564390

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

  • University of Vermont Medical Center, Burlington
  • University of Vermont and State Agricultural College, Burlington
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 22-Ful-2026 · NCT06317649

Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

  • University of Vermont Medical Center, Burlington
  • University of Vermont and State Agricultural College, Burlington
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 hanga 59 · Saalaa hunda · Haaromfame 22-Ful-2026 · NCT05554406

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

  • University of Vermont and State Agricultural College, Burlington
Namoota walitti qabaa jiraSadarkaa 3
6 Months – 21 Years · Saalaa hunda · Haaromfame 17-Ful-2026 · NCT04293562

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

  • University of Vermont Medical Center, Burlington
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 20-Hag-2026 · NCT07007312

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

  • University of Vermont, Burlington
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 20-Hag-2026 · NCT06001788

Kanneen ClinicalTrials.gov irraa argaman, daataa 05-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.